Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) Update for Tuesday, October …

Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) shares will open today at 110.00 after closing yesterday at 83.16.
The stock had changed -0.93% since market close yesterday. In the most recent trading session, company stock traded at a low of 81.43 and a high of
84.75, on average volume of 870805.

Alnylam Pharmaceuticals Incorporated Historical Information

Historically, Alnylam Pharmaceuticals Incorporated has been trading with a 52 week low of 72.06 and a 52 week of high 140.00. Technical indicators show a 50 day
moving average of 94.53. Recent trading put Alnylam Pharmaceuticals Incorporated stock at a -12.14 change from the 50 day moving average, which is
-12.85%.

Additionally, Alnylam Pharmaceuticals Incorporated currently has a market capitalization of 6.97B. Alnylam Pharmaceuticals Incorporated Reported earnings before interest, taxes, debt and amortization (EBITDA) is -200.91M. Earnings per share were -2.35.

Analysts continue to rate Alnylam Pharmaceuticals Incorporated

Sell side brokers and analysts continue to rate Alnylam Pharmaceuticals Incorporated:

The overall rating for the company is 1.63. The rating is an average of the various different ratings given by analysts and brokers to Alnylam Pharmaceuticals Incorporated, and then averaged into one rating by a team of analysts at Zacks in Chicago, Illinois.
For Alnylam Pharmaceuticals Incorporated, the numerical average rating system is as follows:

  1. Strong buy for ALNY
  2. BUY for ALNY
  3. HOLD for ALNY
  4. SELL for ALNY
  5. Strong SELL for ALNY
  • 6 Analysts rate the company a strong buy
  • 1 Analysts rate the company a buy
  • 2 Analysts rate the company a hold
  • 0 Analysts rate the company a sell
  • 0 Analysts rate the company a strong sell

In its most recent quarter Alnylam Pharmaceuticals Incorporated had actual sales of $ 8.685M. Among the 5 analysts who were surveyed, the consensus expectation for quarterly sales had been
14.567M. This represents a -40.378% difference between analyst expectations and the Alnylam Pharmaceuticals Incorporated achieved in its quarterly earnings.

We’ve also learned that Alnylam Pharmaceuticals Incorporated will report its next earnings on November 4, 2015. The earnings report after that one will be on February 11, 2016, and the report for the fiscal year will be made available on February 11, 2016.

Last quarters actual earnings were -0.85 per share.

Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5×15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The Company has three partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV), infection, ALN-VSP for the treatment of liver cancers and ALN-HTT for the treatment of Huntington’s disease (HD).

ALNY and Alnylam Pharmaceuticals Incorporated performance over the last 6 months.